Molecular imaging : radiopharmaceuticals for PET and SPECT
著者
書誌事項
Molecular imaging : radiopharmaceuticals for PET and SPECT
Springer, c2009
- : [hard]
大学図書館所蔵 件 / 全3件
-
該当する所蔵館はありません
- すべての絞り込み条件を解除する
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Radioisotope-based molecular imaging probes provide unprecedented insight into biochemistry and function involved in both normal and disease states of living systems, with unbiased in vivo measurement of regional radiotracer activities offering very high specificity and sensitivity. No other molecular imaging technology including functional magnetic resonance imaging (fMRI) can provide such high sensitivity and specificity at a tracer level. The applications of this technology can be very broad ranging from drug development, pharmacokinetics, clinical investigations, and finally to routine diagnostics in radiology. The design and the development of radiopharmaceuticals for molecular imaging studies using PET/MicroPET or SPECT/MicroSPECT are a unique challenge. This book is intended for a broad audience and written with the main purpose of educating the reader on various aspects including potential clinical utility, limitations of drug development, and regulatory compliance and approvals.
目次
Molecular imaging: introduction. Science of atomism: a brief history. Atoms and radiation. Radioactivity. Production of radionuclides. PET and SPECT scanners. Chemistry: basic principles. Cell and molecular biology. Radiopharmaceuticals. Chemistry of radiohalogens (F, Br and I). Chemistry of organic radionuclides (C, N, and O). Chemistry of metal radionuclides (Rb, Ga, In, Y, Cu and Tc). Quality control of radiopharmaceuticals. Mechanisms of radiopharmaceutical transport and localization. Pharmacokinetics and modeling. Molecular imaging in oncology. Molecular imaging in cardiology. Molecular imaging in neurology and psychiatry. Molecular imaging of gene expression. Molecular imaging in drug development. Radiation dosimetry and protection. Radiopharmaceuticals, GMPs and regulatory issues.
「Nielsen BookData」 より